Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT6616
- Development stage
- Preclinical
- Lead developer
- Jiangsu Atom Bioscience & Pharmaceutical
- Modality
- Small Molecules
01
Overview
AT6616 is a preclinical drug candidate being developed by Atom Bioscience (also known as Atom Therapeutics) for the treatment of metabolic and cardiovascular diseases. As part of Atom Bioscience's pipeline, which focuses on the development of small molecule therapeutics for chronic diseases, AT6616 is currently undergoing preclinical evaluation to determine its safety and efficacy profile. While specific details regarding its biological target and mechanism of action have not been publicly disclosed, the compound represents the company's expansion into metabolic and cardiovascular indications beyond its primary focus on inflammatory conditions such as gout.
- Other names
- Atom PharmaAtom Therapeutics
Beyond the preview
Go deeper on AT6616.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT6616.